Medical Management of Cancer-treatment Induced Emesis (Record no. 8526)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01245 a2200265 4500 |
| 001 - CONTROL NUMBER | |
| control field | 1040290485 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250328151426.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250324042024xx eng |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781040290484 |
| Qualifying information | EA |
| 037 ## - SOURCE OF ACQUISITION | |
| Source of stock number/acquisition | Taylor & Francis |
| Terms of availability | GBP 115.00 |
| Form of issue | BB |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | 01 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| 072 7# - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | thema |
| 072 7# - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | bic |
| 072 7# - SUBJECT CATEGORY CODE | |
| Subject category code | MED045000 |
| Source | bisac |
| 072 7# - SUBJECT CATEGORY CODE | |
| Subject category code | MED000000 |
| Source | bisac |
| 072 7# - SUBJECT CATEGORY CODE | |
| Subject category code | MED062000 |
| Source | bisac |
| 072 7# - SUBJECT CATEGORY CODE | |
| Subject category code | 616.994061 |
| Source | bisac |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Mario A. Dicato |
| 245 10 - TITLE STATEMENT | |
| Title | Medical Management of Cancer-treatment Induced Emesis |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | CRC Press |
| Date of publication, distribution, etc. | 20241101 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 248 p |
| 520 ## - SUMMARY, ETC. | |
| Expansion of summary note | Nausea and vomiting are two of the most common side-effects of anti-cancer treatment, and the discovery and clinical application of 5-hydroxytryptamine3 receptor antagonists has transformed the management of these side effects, resulting in a much improved quality of life for cancer patients. This text presents a detailed overview of the management of cancer-treatment induced emesis in a number of different treatment settings, and focuses on the mechanisms and use of 5-HT3 receptor antagonists. Contributions are also included from the points of view of the nurse and the patient. |
No items available.